Of these, 568 patients were excluded (245 had a hormone-receptor-positive and/or a HER2-positive tumor, 277 had a previous history of cancer, 30 patients had metastatic cancer at diagnosis, 13 had had breast surgery before the PET/CT examination and 3 patients did not present hypermetabolic lesions in the PET/CT). The gene discussed is ERBB2; the disease is cancer.